Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Combination of Cd34-Positive Cell Subsets with Infarcted Myocardium-Like Matrix Stiffness: A Potential Solution to Cell-Based Cardiac Repair

Reply to Letter from Drs. Haider and Ashraf

A Role of Myocardial Stiffness in Cell-Based Cardiac Repair: a Hypothesis

Statin and Stromal Cell-Derived Factor-1 Additively Promote Angiogenesis

Infarcted myocardium-like stiffness contributes to endothelial progenitor lineage commitment of bone marrow mononuclear cells.

Bone Marrow CD34+ Cell Subset under Induction of Moderate Stiffness of Extracellular Matrix after Myocardial Infarction Facilitated Endothelial Lineage Commitment in Vitro

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Inflammatory Cytokines Alter Mesenchymal Stem Cell Mechanosensing and Adhesion on Stiffened Infarct Heart Tissue after Myocardial Infarction.

Multilineage Contribution of CD34+ Cells in Cardiac Remodeling after Ischemia/reperfusion Injury.

Abstract 19996: Cardiac Mesenchymal Stem Cells with High Endogenous Gata4 Promoter Activity Have Superior Capacity to Elicit Cardiac Repair

Local Activation of Cardiac Stem Cells for Post-Myocardial Infarction Cardiac Repair

Combining ECM Hydrogels of Cardiac Bioactivity with Stem Cells of High Cardiomyogenic Potential for Myocardial Repair

Cardiac commitment driven by MyoD expression in pericardial stem cells

Extracellular Matrix/Glycopeptide Hybrid Hydrogel as an Immunomodulatory Niche for Endogenous Cardiac Repair after Myocardial Infarction

Pericardial Delivery of SDF‐1α‐encapsulated Puerarin Hydrogel Promotes Endogenous Repair and Electrical Coupling After Myocardial Infarction

Cartilage-Derived Strornal Cells: Is It A Novel Cell Resource For Cell Therapy To Regenerate Infarcted Myocardium?

Comparison of Various Kinds of Bone Marrow Stem Cells for the Repair of Infarcted Myocardium: Single Clonally Purified Non-Hematopoietic Mesenchymal Stem Cells Serve As a Superior Source

Improving Cell Engraftment in Cardiac Stem Cell Therapy.

Extracellular matrix remodeling following myocardial infarction influences the therapeutic potential of mesenchymal stem cells

Central Zone of Myocardial Infarction: a Neglected Target Area for Heart Cell Therapy

Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury